ClinicalTrials.gg
Active, not recruitingNCT03155061Updated Sep 4, 2026

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of ONO-4578 and ONO-4538 in Advanced or Metastatic Solid Tumors, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 22 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
183
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced or solid tumors (Part A, B)
  • Unresectable, advanced or recurrent gastric cancer previously treated with anti-PD-(L)1 antibodies or naive to anti-PD-(L)1 antibodies (Part C)
  • Unresectable, advanced or recurrent colorectal cancer(Part D)
  • of at least 3 months
  • Patients with performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Patients with severe complication
  • Patients with multiple primary cancers
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
183 participants (estimated)

Study arms

  • Experimental
    Part A (Dose Escalation Part): ONO-4578 monotherapy

    ONO-4578 specified dose on specified days in advanced or metastatic solid tumors

    Drug: ONO-4578

  • Experimental
    Part B: ONO-4578 in combination with ONO-4538

    ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors

    Drug: ONO-4578 · Drug: ONO-4538

  • Experimental
    Part C (Expansion Part): ONO-4578 in combination with ONO-4538

    ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer

    Drug: ONO-4578 · Drug: ONO-4538

  • Experimental
    Part D (Expansion Part): ONO-4578 in combination with ONO-4538

    ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer

    Drug: ONO-4578 · Drug: ONO-4538

Interventions

  • ONO-4578 specified dose on specified days

  • ONO-4538 specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety (adverse event, clinical laboratory test, 12-lead electrocardiography, chest X-ray, ECOG performance status)

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Maximum observed serum concentration(Cmax)

    Time frame: Up to Cycle 1 (each cycle is 28 days)

  2. Area Under the blood concentration-time Curve(AUC)

    Time frame: Up to Cycle 1 (each cycle is 28 days)

  3. Half-life(T1/2) of ONO-4578 both alone and in combination with ONO-4538

    Time frame: Up to Cycle 1 (each cycle is 28 days)

07

Study locations

22 sites
  • Aichi Clinical Site 1
    Nagoya, Aichi-ken, Japan
  • Aichi Clinical Site 2
    Toyoake, Aichi-ken, Japan
  • Chiba Clinical Site 1
    Kashiwa, Chiba, Japan
  • Ehime Clinical Site1
    Matsuyama, Ehime, Japan
  • Fukuoka Clinical Site 1
    Fukuoka, Fukuoka, Japan
  • Fukuoka Clinical Site 2
    Fukuoka, Fukuoka, Japan
  • Gunma Clinical Site 1
    Ōta, Gunma, Japan
  • Hokkaido Clinical Site 1
    Sapporo, Hokkaido, Japan
  • Iwate Clinical Site 1
    Yahaba-cho, Iwate, Japan
  • Kanagawa Clinical Site 2
    Sagamihara, Kanagawa, Japan
  • Kanagawa Clinical Site 1
    Yokohama, Kanagawa, Japan
  • Osaka Clinical Site 2
    Hirakata, Osaka, Japan
  • Osaka Clinical Site 1
    Osaka, Osaka, Japan
  • Osaka Clinical Site 3
    Sakai, Osaka, Japan
  • Osaka Clinical Site 4
    Takatsuki, Osaka, Japan
  • Saitama Clinical Site 2
    Hidaka, Saitama, Japan
  • Saitama Clinical Site 1
    Ina-machi, Saitama, Japan
  • Shizuoka Clinical Site 1
    Nagaizumi-Cho, Shizuoka, Japan
  • Tokyo Clinical Site 1
    Chuo-ku, Tokyo, Japan
  • Tokyo Clinical Site 4
    Itabashi-ku, Tokyo, Japan
  • Tokyo Clinical Site 2
    Koto-ku, Tokyo, Japan
  • Tokyo Clinical Site 3
    Shinjyuku-ku, Tokyo, Japan
08

References and documents

Publications

  • Kawazoe A, Yamaguchi K, Hamaguchi T, Narita Y, Boku S, Oshima T, Hara H, Hamamoto Y, Ishido K, Esaki T, Hosaka H, Yasui H, Koeda K, Nishina T, Tsuji Y, Fukagawa T, Goto M, Oki E, Sugimoto N, Matsuoka H, Yokoyama F, Yoshida T, Yoshida K, Oshima Y, Iwasa S. ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. Cancer Sci. 2025 Sep;116(9):2523-2536. doi: 10.1111/cas.70130. Epub 2025 Jul 6. PubMed 40618725 ↗
  • Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer Sci. 2023 Jan;114(1):211-220. doi: 10.1111/cas.15574. Epub 2022 Nov 4. PubMed 36082616 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2017 (actual). Primary completion is estimated for Mar 2028, 131 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2017
First posted
May 16, 2017
StartActual
Apr 19, 2017
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03155061
Responsible party
Sponsor
First posted
May 16, 2017
Start date
Apr 19, 2017
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-986310

Start the discussion